Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-21-042017
Filing Date
2021-08-12
Accepted
2021-08-12 16:07:50
Documents
90
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0621_immucellcorp.htm   iXBRL 10-Q 1086421
2 CERTIFICATION f10q0621ex31_immucellcorp.htm EX-31 8137
3 CERTIFICATION f10q0621ex32_immucellcorp.htm EX-32 4708
  Complete submission text file 0001213900-21-042017.txt   6300965

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE iccc-20210630.xsd EX-101.SCH 71750
5 XBRL CALCULATION FILE iccc-20210630_cal.xml EX-101.CAL 30451
6 XBRL DEFINITION FILE iccc-20210630_def.xml EX-101.DEF 286170
7 XBRL LABEL FILE iccc-20210630_lab.xml EX-101.LAB 571503
8 XBRL PRESENTATION FILE iccc-20210630_pre.xml EX-101.PRE 303188
9 EXTRACTED XBRL INSTANCE DOCUMENT f10q0621_immucellcorp_htm.xml XML 897837
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12934 | Film No.: 211167556
SIC: 2835 In Vitro & In Vivo Diagnostic Substances